NVIV - InVivo is up after peer-reviewed publication of study on spinal cord injury
InVivo Therapeutics ([[NVIV]] +5.4%) is trading higher today in above-average volume after the company announced the publication of a peer-reviewed manuscript describing the complete six-month primary endpoint results from its single-arm INSPIRE 1.0 study.The publication in the Journal of Neurosurgery: Spine includes complete six-month primary endpoint results from the study that evaluated its Neuro-Spinal Scaffold in patients with complete thoracic AIS A spinal cord injury. The results were first announced in 2018.The company has officially closed the trial and the enrollment is underway for a second pivotal clinical study of the Neuro-Spinal Scaffold™ in patients with acute SCI (INSPIRE 2.0).The 12-month data of the study were disclosed in April 2019.
For further details see:
InVivo is up after peer-reviewed publication of study on spinal cord injury